Royalty Pharma Sub-Manager, LLC

CIK 0002081668 · NEW YORK, NY · Quarter end: 2025-12-31 · Filed on: 2026-08-21 · Open the SEC source ↗

The most recent 13F EDGAR holds under this CIK is 2025 Q4, filed 2026-08-21. Nothing has been filed since — the fund stopped filing, or it files under a different entity now. The positions below are a snapshot of that date, not a current portfolio.

Royalty Pharma Sub-Manager, LLC reported 4 positions worth $171.3M as of December 31, 2025 (13F filed August 21, 2026). Largest holding: CYTK (36.4%).

Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.

$171.3M

2025 Q4

Positions

Top-10 ConcentrationHow much of the portfolio sits in the 10 largest holdings. High = concentrated bets.

100.0%

Est. Net Flow (Q)

—

2025 Q4

Positions Changes Mix History BacktestPRO

4 positions shown

#	Symbol	Company	Type	Value ↓	% Port.	Shares	1Y	YTD
▸ 1	CYTK	CYTOKINETICS, INC	SH	$62.3M	36.36%	980,392	—	—
▸ 2	ZBIO	ZENAS BIOPHARMA, INC.	SH	$45.9M	26.77%	1,263,150	—	—
▸ 3	BHVN	BIOHAVEN LTD	SH	$33.2M	19.35%	2,936,507	—	—
▸ 4	BCRX	BIOCRYST PHARMACEUTICALS INC	SH	$30.0M	17.51%	3,846,154	—	—

Read the 2026-Q2 quarterly report · 13F Filing Calendar

Frequently Asked Questions

What stocks does Royalty Pharma Sub-Manager, LLC hold as of Q4 2025?

Royalty Pharma Sub-Manager, LLC reported 4 positions worth $171.3M in its Q4 2025 13F filing. Largest positions: CYTK (36.4%), ZBIO (26.8%), BHVN (19.4%) and BCRX (17.5%).

What did Royalty Pharma Sub-Manager, LLC buy in Q4 2025?

No previous quarter is available yet; the comparison appears with the next filing.

What did Royalty Pharma Sub-Manager, LLC sell in Q4 2025?

No previous quarter is available yet.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.